Michael D. West

Michael D. West is a declared insider at 3 companies (chief executive); the most frequent names are Serina Therapeutics, Inc., Lineage Cell Therapeutics, Inc. and Ocata Therapeutics, Inc. We count 52 filings; the first trade dates from 9 October 2007 and the latest from 11 March 2023.

On the open market, the record shows 4 purchases worth €81k and 1 sale worth €531k. Sales outweigh purchases by €450k. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Besides market trades, the filings include 21 share grants and 26 option exercises.

A typical purchase (the median) is worth €22k. For 4 purchases whose 90-day window has closed, the share price was higher on day 90 than the day after publication in 25% of cases, with a median move of -2.5%. They describe history only and say nothing certain about the share price ahead.

The record was last updated on 14 March 2023 with a share grant (€591) in Serina Therapeutics, Inc. The last insider purchase was made public on 12 December 2018, 2,888 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. For comparison, the SEC allows two business days to file a Form 4. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.